Insilico Medicine (HK:03696), an artificial intelligence (AI)-driven drug discovery company, announced on Sunday that it has agreed a multi-year research and development (R&D) collaboration with Servier, a France-based international pharmaceutical company governed by a foundation.

This strategic alliance is focused on identifying and developing novel therapeutics for challenging oncology targets by leveraging Insilico's proprietary AI platform, Pharma.AI.

Under the agreement, Insilico will be eligible to receive up to USD32m in upfront and near-term R&D payments and will lead the AI-driven discovery and development of potential drug candidates that meet predefined criteria. Servier will share research and development costs, and, upon the successful identification of promising candidates, will lead subsequent clinical validation, regulatory interactions, and worldwide commercialisation of the resulting oncology drug candidates.